Results 1 - 20 of 1,497 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Show only
- Peer-reviewed Journals (1,409)
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialThe Lancet (British edition), 2019-06, Vol.393 (10189), p.2404-2415 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)30723-8 ;PMID: 31079938Full text available |
| 2 |
Material Type: Article
|
|
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed studyHaematologica (Roma), 2021-08, Vol.106 (8), p.2161-2169 [Peer Reviewed Journal]Copyright© 2021 Ferrata Storti Foundation ;ISSN: 0390-6078 ;EISSN: 1592-8721 ;DOI: 10.3324/haematol.2020.261859 ;PMID: 32675221Full text available |
| 3 |
Material Type: Article
|
|
Evolving therapeutic landscape of advanced hepatocellular carcinomaNature reviews. Gastroenterology & hepatology, 2023-04, Vol.20 (4), p.203-222 [Peer Reviewed Journal]2022. Springer Nature Limited. ;Springer Nature Limited 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;ISSN: 1759-5045 ;EISSN: 1759-5053 ;DOI: 10.1038/s41575-022-00704-9 ;PMID: 36369487Full text available |
| 4 |
Material Type: Article
|
|
Management of glioblastoma: State of the art and future directionsCA: a cancer journal for clinicians, 2020-07, Vol.70 (4), p.299-312 [Peer Reviewed Journal]2020 American Cancer Society ;2020 American Cancer Society. ;Copyright Wiley Subscription Services, Inc. Jul/Aug 2020 ;ISSN: 0007-9235 ;EISSN: 1542-4863 ;DOI: 10.3322/caac.21613 ;PMID: 32478924Full text available |
| 5 |
Material Type: Article
|
|
Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment ResponseClinical cancer research, 2016-12, Vol.22 (23), p.5765-5771 [Peer Reviewed Journal]2016 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-16-0702 ;PMID: 27803067Full text available |
| 6 |
Material Type: Article
|
|
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)The Lancet (British edition), 2017-10, Vol.390 (10103), p.1654-1663 [Peer Reviewed Journal]2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 7, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)31607-0 ;PMID: 28756902Full text available |
| 7 |
Material Type: Article
|
|
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeCancer cell, 2020-12, Vol.38 (6), p.803-817.e4 [Peer Reviewed Journal]2020 Elsevier Inc. ;Copyright © 2020 Elsevier Inc. All rights reserved. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2020.10.011 ;PMID: 33157048Full text available |
| 8 |
Material Type: Article
|
|
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaNature communications, 2016-08, Vol.7 (1), p.12624-12624, Article 12624 [Peer Reviewed Journal]Copyright Nature Publishing Group Aug 2016 ;Copyright © 2016, The Author(s) 2016 The Author(s) ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/ncomms12624 ;PMID: 27571927Full text available |
| 9 |
Material Type: Article
|
|
Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-AnalysisJNCI : Journal of the National Cancer Institute, 2022-04, Vol.114 (4), p.503-516 [Peer Reviewed Journal]The Author(s) 2021. Published by Oxford University Press. 2021 ;The Author(s) 2021. Published by Oxford University Press. ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djab106 ;PMID: 34077519Full text available |
| 10 |
Material Type: Article
|
|
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast CancerJournal of clinical oncology, 2022-04, Vol.40 (12), p.1323-1334 [Peer Reviewed Journal]2022 by American Society of Clinical Oncology 2022 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.21.01506 ;PMID: 35044810Full text available |
| 11 |
Material Type: Article
|
|
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living GuidelineJournal of clinical oncology, 2022-10, Vol.40 (28), p.3323-3343 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.22.00825 ;PMID: 35816668Full text available |
| 12 |
Material Type: Article
|
|
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized TrialCancer cell, 2018-05, Vol.33 (5), p.829-842.e5 [Peer Reviewed Journal]2018 The Author(s) ;Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;2018 The Author(s) 2018 ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2018.04.004 ;PMID: 29763623Full text available |
| 13 |
Material Type: Article
|
|
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastasesNature medicine, 2016-11, Vol.22 (11), p.1294-1302 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Nov 2016 ;ISSN: 1078-8956 ;ISSN: 1546-170X ;EISSN: 1546-170X ;DOI: 10.1038/nm.4197 ;PMID: 27748747Full text available |
| 14 |
Material Type: Article
|
|
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialThe Lancet (British edition), 2023-11, Vol.402 (10415), p.1835-1847 [Peer Reviewed Journal]2023 Elsevier Ltd ;Copyright © 2023 Elsevier Ltd. All rights reserved. ;2023. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(23)01796-8 ;PMID: 37871608Full text available |
| 15 |
Material Type: Article
|
|
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyThe lancet oncology, 2015-10, Vol.16 (13), p.1306-1315 [Peer Reviewed Journal]Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 2015 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(15)00122-9 ;PMID: 26338525 ;CODEN: LANCAOFull text available |
| 16 |
Material Type: Article
|
|
Efficacy and tolerability of bevacizumab in patients with severe Covid-19Nature communications, 2021-02, Vol.12 (1), p.814-814, Article 814 [Peer Reviewed Journal]The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-021-21085-8 ;PMID: 33547300Full text available |
| 17 |
Material Type: Article
|
|
Anti‐vascular endothelial growth factor for neovascular age‐related macular degenerationCochrane database of systematic reviews, 2019-03, Vol.2019 (3), p.CD005139 [Peer Reviewed Journal]Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD005139.pub4 ;PMID: 30834517Full text available |
| 18 |
Material Type: Article
|
|
Treatment of recurrent ovarian cancerAnnals of oncology, 2017-11, Vol.28 (suppl_8), p.viii51-viii56 [Peer Reviewed Journal]The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdx441 ;PMID: 29232464Full text available |
| 19 |
Material Type: Article
|
|
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialAnnals of oncology, 2019-11, Vol.30 (11), p.1796-1803 [Peer Reviewed Journal]2019 European Society for Medical Oncology ;The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. ;The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. 2019 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz387 ;PMID: 31868905Full text available |
| 20 |
Material Type: Article
|
|
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)Clinical cancer research, 2024-01, Vol.30 (1), p.176-186 [Peer Reviewed Journal]2023 The Authors; Published by the American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-23-0771 ;PMID: 37527007Full text available |
Results 1 - 20 of 1,497 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Personalize your results
Refine Search Results
Expand My Results
Show only
- Peer-reviewed Journals (1,409)
Refine My Results
Creation Date
- Before 2013 (5)
- 2013 To 2015 (213)
- 2016 To 2018 (514)
- 2019 To 2022 (537)
- After 2022 (229)
-
More options
New Records
Resource Type
- Articles (1,494)
- Book Chapters (3)
-
More options
Subject
- Bevacizumab - Therapeutic Use (1,488)
- Humans (1,466)
- Science & Technology (1,336)
- Life Sciences & Biomedicine (1,240)
- Female (853)
- Bevacizumab (769)
- Angiogenesis Inhibitors - Therapeutic Use (714)
- Male (711)
- Middle Aged (613)
- Oncology (555)
- Aged (540)
- Adult (399)
- Treatment Outcome (376)
- Vascular Endothelial Growth Factor (370)
- Retrospective Studies (361)
- Monoclonal Antibodies (349)
- Patients (336)
- Ophthalmology (325)
- Intravitreal Injections (324)
- Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use (308)
-
More options
Databases
- MEDLINE (1,492)
- ProQuest Central (920)
- PubMed Central (755)
- Freely Accessible Journals (665)
- DOAJ Directory of Open Access Journals (599)
- ROAD: Directory of Open Access Scholarly Resources (454)
- Springer_OA刊 (231)
- HighWire Press (Free Journals) (185)
- Nature (Open access) (114)
- Journals@Ovid Open Access Journal Collection Rolling (87)
- Open Access: Wiley-Blackwell Open Access Journals (74)
- IngentaConnect Open Access Journals (62)
- PLoS (Open access) (55)
- Wolters Kluwer Open Health (47)
- Open Access: Freely Accessible Journals by multiple vendors (38)
- Taylor & Francis Open Access (30)
- BMJ Open Access Journals (29)
- Medknow Open Access Medical Journals (28)
- Freely Accessible Japanese Titles (ERDB Project) (27)
- ProQuest One Psychology (27)
-
More options
Language
Journal Title
- American Journal Of Ophthalmology (37)
- Bmc Cancer (29)
- Eye (43)
- Journal Of Neuro-Oncology (60)
- Medicine (47)
- Neuro-Oncology (29)
- Ophthalmic Surgery, Lasers & Imaging (39)
- Ophthalmic Surgery, Lasers & Imaging Retina (39)
- Plos One (55)
- Scientific Reports (35)
-
More options
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||